CSBIO(SZ:300255)2021-08-27 16:00Financial Performance - The company's operating revenue for the first half of 2021 was CNY 1,417,401,504.14, representing a 40.36% increase compared to CNY 1,009,847,609.95 in the same period last year[25]. - Net profit attributable to shareholders of the listed company reached CNY 156,960,062.38, up 20.13% from CNY 130,654,169.65 in the previous year[25]. - The net cash flow from operating activities was CNY 118,591,701.88, a significant improvement of 128.46% compared to a negative cash flow of CNY 416,676,745.13 in the same period last year[25]. - Basic earnings per share increased to CNY 0.17, reflecting a growth of 21.43% from CNY 0.14 in the previous year[25]. - Total assets at the end of the reporting period were CNY 4,583,617,900.37, a slight increase of 0.24% from CNY 4,572,556,783.14 at the end of the previous year[25]. - Net assets attributable to shareholders of the listed company rose to CNY 2,999,468,868.63, marking a 5.33% increase from CNY 2,847,580,472.06 at the end of the previous year[25]. - The weighted average return on net assets was 5.37%, an increase of 0.69% compared to 4.68% in the previous year[25]. - The company reported a net profit after deducting non-recurring gains and losses of CNY 152,666,257.93, which is a 17.04% increase from CNY 130,437,911.69 in the previous year[25]. Market Position and Product Development - The company maintains a leading market share in low molecular weight heparin calcium injection, with widespread recognition in the market[43]. - The company is one of the few in China with a complete heparin product industrial chain, engaging in the R&D, production, and sales of heparin raw materials and preparations[43]. - The company’s core product, low molecular weight heparin calcium injection, accounts for over 10% of its main business revenue[37]. - The company is currently developing a Class I new drug, a GLP-1 long-acting preparation for the treatment of type II diabetes, which has entered the clinical phase III[37]. - The company has been recognized as a national high-tech enterprise and has established a drug research institute to enhance its R&D capabilities[37]. - The company is actively expanding its product range and optimizing management mechanisms to enhance market competitiveness[43]. - The company is focusing on the R&D of heparin series products, hyaluronic acid series products, and new drugs like Aibennapeptide[60]. Revenue Sources - Heparin preparations generated revenue of 803.41 million yuan, a year-on-year increase of 35.90%[44]. - Sales revenue from heparin raw materials reached 575.40 million yuan, up 42.27% year-on-year[45]. - The sales volume and price of heparin raw materials have increased, contributing to the company's revenue growth[43]. Investment and Financial Management - The total investment during the reporting period was ¥5,050,000.00, reflecting a significant increase of 98.04% compared to ¥2,550,000.00 in the previous year[75]. - The total amount raised from the non-public offering was RMB 60,000 million, with a net amount of RMB 58,335.29 million after expenses[78]. - The interest income from the raised funds amounted to RMB 1,377.69 million, with RMB 3,067.14 million utilized from the special account[78]. - The company committed to invest a total of RMB 58,335.2 million in projects, with RMB 1.89 million invested during the reporting period, achieving an investment progress of 28.53%[79]. Environmental Compliance - The company processed a total of 21,750 tons of wastewater in the first half of 2021, with no instances of exceeding discharge standards[126]. - The subsidiary, Kaikede, processed 55,119 tons of wastewater during the same period, also with no exceedances in discharge standards[126]. - The company generated a total of 24.3256 tons of hazardous waste in the first half of 2021, all of which was disposed of by qualified units[132]. - The company achieved a 100% pass rate in the LDAR testing for VOCs, effectively reducing unorganized emissions and air pollution[132]. - The company has maintained stable operations of its wastewater treatment facilities, ensuring compliance with environmental standards throughout the reporting period[126]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[129]. - The company has implemented a comprehensive environmental monitoring plan, with all monitored parameters meeting discharge standards[128]. Shareholder Information - The total number of shares increased from 934,966,878 to 934,966,878, with a slight increase in restricted shares from 253,271,828 to 253,489,328[167]. - The company’s management increased their holdings, with Vice President Li Zhihua acquiring 190,000 shares and CFO Wang Jun acquiring 100,000 shares during the reporting period[167]. - The total number of common shareholders at the end of the reporting period is 32,024[174]. - The largest shareholder, Gao Shuhua, holds 35.69% of the shares, totaling 333,644,728 shares[174]. - The second-largest shareholder, Guotou High-tech Investment Co., Ltd., holds 12.56%, amounting to 117,403,020 shares[174]. Risks and Challenges - The company is facing risks from policy and industry changes, which could impact drug production and competition[104]. - Rising procurement costs for heparin crude products are a concern, prompting the company to monitor market prices closely and enhance self-supply capabilities[107]. - The company reported that the sales growth of heparin preparations was below expectations, leading to a reassessment of investment projects[79]. Legal and Compliance Matters - The company did not engage in any related party transactions during the reporting period[145]. - The company reported a litigation amount of 1.3186 million yuan related to a contract dispute with Beijing Jiacheng Pharmaceutical Co., Ltd.[143]. - There were no significant penalties or rectifications during the reporting period[144]. - The company has not experienced any significant litigation or arbitration matters during the reporting period[141].